GlassScriptPhysician profile
Aniq Shaikh
NPI 1043209695
$13,781.41
in general payments reported to CMS, 2019-2025
43 companies · $2,204 in 2025
The $2,204 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,115 · 2020: $1,490 · 2021: $1,772 · 2022: $1,736 · 2023: $2,149 · 2024: $2,315 · 2025: $2,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,600 · Education: $67.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,600.40 |
| Education | $67.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,303.05 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Abbvie INC. | $2,761.46 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,219.94 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $882.55 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Phathom Pharmaceuticals, INC. | $734.88 | 2024-2025 | Voquezna |
| Pfizer INC. | $545.26 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $537.07 | 2019-2024 | Ocaliva |
| Celgene Corporation | $469.40 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $364.92 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $326.37 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $323.70 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $313.90 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $249.86 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $223.07 | 2019-2024 | Dificid, Bridion |
| Ardelyx, INC. | $209.54 | 2023-2025 | Ibsrela |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $122.58 | 2019-2023 | Suflave |
| Ucb, INC. | $122.27 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $120.35 | 2019 | |
| Allergan, INC. | $110.66 | 2019 | |
| Amgen INC. | $103.24 | 2019 | |
| Nestle Healthcare Nutrition INC. | $93.66 | 2021 | |
| Redhill Biopharma INC. | $84.43 | 2020-2022 | |
| Romark Laboratories, Lc | $67.42 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $67.40 | 2025 | Iqirvo |
| Genzyme Corporation | $53.42 | 2022-2025 | |
| Daiichi Sankyo INC. | $40.86 | 2021-2023 | Injectafer |
| Celltrion USA INC. | $39.63 | 2024 | Zymfentra |
| Novo Nordisk INC | $31.99 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $31.16 | 2021-2025 | Rebyota |
| Evoke Pharma, INC. | $30.51 | 2022-2023 | Gimoti |
| Enterra Medical, INC. | $26.59 | 2023 | |
| Mallinckrodt Hospital Products INC. | $24.36 | 2020 | |
| Vivus LLC | $23.76 | 2023 | Pancreaze |
| Guard Medical INC. | $23.15 | 2025 | Npseal |
| Axonics, INC. | $18.92 | 2023 | Axonics |
| Alexion Pharmaceuticals, INC. | $18.68 | 2021 | |
| Covidien LP | $18.52 | 2019 | |
| Medtronic, INC. | $15.18 | 2021 | |
| Qol Medical, LLC | $14.00 | 2021 | |
| Ethicon US, LLC | $13.70 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aniq Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.